NORTHRIDGE, Calif.--(BUSINESS WIRE)--Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
